Related Experiment Videos
Multicenter analytical performance evaluation of the Elecsys proBNP assay
Lori J Sokoll1, Hannsjörg Baum, Paul O Collinson
1Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA. lsokoll@jhmi.edu
Clinical Chemistry and Laboratory Medicine
|September 25, 2004
Summary
The Elecsys proBNP assay demonstrates strong technical performance for diagnosing congestive heart failure. This automated immunoassay offers reliable precision and accuracy, making it suitable for routine clinical use.
Area of Science:
- Clinical Chemistry
- Immunoassay Technology
- Cardiovascular Diagnostics
Background:
- Congestive heart failure (CHF) diagnosis relies on accurate biomarker measurement.
- N-terminal pro-brain natriuretic peptide (NT-proBNP) is a key biomarker for CHF.
- Automated assays are crucial for efficient clinical laboratory workflows.
Purpose of the Study:
- To evaluate the technical performance of the automated Elecsys proBNP assay.
- To assess the assay's suitability as an aid in diagnosing congestive heart failure.
- To validate the assay across multiple platforms and international sites.
Main Methods:
- Multicenter study involving three Elecsys analyzers (E 1010, E 2010, E 170) at eight sites.
- Evaluation of within-run, total precision, and inter-site/platform reproducibility.
- Assessment of linearity, assay interference, sample matrix effects, and analyte stability.
Main Results:
- Excellent precision (<3% within- and total), with high reproducibility (<5% among sites/platforms).
- Accurate linearity up to 25,000 pg/ml and minimal interference observed.
- NT-proBNP concentrations were stable and unaffected by sample type, storage, or collection variables.
Conclusions:
- The Elecsys proBNP assay exhibits robust technical performance characteristics.
- The assay is suitable for routine clinical laboratory use in diagnosing congestive heart failure.
- Reliable performance supports its role as an aid in CHF diagnosis.